Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Treasurer of the State of North Carolina

Treasurer of the State of North Carolina grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 71.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 175,980 shares of the medical equipment provider's stock after acquiring an additional 73,180 shares during the period. Treasurer of the State of North Carolina owned about 0.08% of Hologic worth $12,686,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. General Partner Inc. bought a new stake in shares of Hologic in the 4th quarter valued at about $26,000. Venturi Wealth Management LLC increased its holdings in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC raised its stake in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after buying an additional 159 shares during the period. Finally, Smithfield Trust Co boosted its position in Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Remove Ads

Hologic Stock Performance

HOLX traded down $1.36 on Wednesday, reaching $56.50. 3,256,993 shares of the stock were exchanged, compared to its average volume of 1,929,097. The company's 50-day moving average price is $61.87 and its 200 day moving average price is $71.15. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market capitalization of $12.68 billion, a PE ratio of 17.82, a PEG ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a fifty-two week low of $56.06 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HOLX has been the subject of several recent research reports. Morgan Stanley reduced their price target on Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Royal Bank of Canada decreased their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research report on Thursday, February 6th. William Blair reaffirmed an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective for the company. in a research note on Monday, February 3rd. Finally, Stephens restated an "overweight" rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Hologic presently has an average rating of "Hold" and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.